amodiaquine
Trade name: camoquin
Amodiaquine is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. The drug binds the free heme preventing the parasite from converting it to a form less toxic. This drug-heme complex is toxic and disrupts membrane function. The side effects of amodiaquine are generally minor to moderate and are similar to those of chloroquine. Rarely liver problems or low blood cell levels may occur. When taken in excess headaches, trouble seeing, seizures, and cardiac arrest may occur. After oral administration amodiaquine hydrochloride is rapidly absorbed,and undergoes rapid and extensive metabolism to desethylamodiaquine which concentrates in red blood cells. It is likely that desethylamodiaquine, not amodiaquine, is responsible for most of the observed antimalarial activity, and that the toxic effects of amodiaquine after oral administration may in part be due to desethylamodiaquine. — NCATS
Clinical trial activity
121 trials · 144 clinical orgs · 1 marketing orgs
Earliest trial started Mar 1, 2001 (NCT00137514)
Timeline
1950s
- Jun 1, 1950
Parke-Davis — First NDA Organization
- Jun 1, 1950
Parke-Davis — NDA Organization
Indications
Approved for
Studied for
- Anemia · Phase 4
- Anemia, Sickle Cell · Phase 1/Phase 2
- Child · Phase 4
- COVID-19 · Phase 2
- Drug Combinations · Phase 1/Phase 2
- Fever · Phase 3
- Healthy Volunteers · Phase 4
- HIV · Phase 4
- Malaria, Falciparum · Phase 4
- Malaria, Vivax · Phase 3
- Malnutrition · Phase 4
- Only Child · Phase 3
- Pharmacokinetics · Phase 1/Phase 2
- Plasmodium falciparum · Phase 4
- Pregnancy · Phase 3
- Pregnancy Complications · Phase 3
- Respiratory Tract Infections · Phase 3
Mechanism of action
- Ferriprotoporphyrin IXINHIBITOR
Ferriprotoporphyrin IX inhibitor
prevents crystallisation
Approval history
- approved—
Chemistry & pharmacology
SMILES
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O- Mol. weight
- 355.87 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL682 ↗
- WikipediaAmodiaquine ↗
- NCATS220236ED28 ↗
- ChEMBLCHEMBL1630 ↗
- ChEMBLCHEMBL1357648 ↗
Also known as
- amiodiaquine
- amodiaquin
- amodiaquina
- amodiaquina
- amodiaquin dihydrochloride
- amodiaquin dihydrochloride dihydrate
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine
- amodiaquine hcl
- amodiaquine hcl
- amodiaquine hcl
- amodiaquine hydrochloride
- amodiaquine hydrochloride
- amodiaquine hydrochloride
- amodiaquine hydrochloride
- amodiaquinum
- amodiaquinum
- camochin
- camoquin
- camoquin
- camoquin
- camoquin
- camoquin
- camoquinal
- camoquine
- camoquin hcl
- camoquin hcl
- camoquin hcl
- camoquin hydrochloride
- flavoquine
- flavoquine
- flavoquine
- gnf-pf-5648
- gnf-pf-5648
- sj000110703
- sj000110703
- sunoquine
- tcmdc-123932
- tcmdc-123932
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06967519 | Phase 4 | Dec 31, 2025 | National Institutes of Health (NIH), Yale University |
| NCT06083688 | Phase 4 | Oct 31, 2024 | Kamuzu University of Health Sciences, University of Liverpool |
| NCT06182176 | N/A | May 27, 2024 | Kintampo Health Research Centre, Ghana, University of London |
| NCT06173206 | Phase 3 | Mar 15, 2024 | University of London |
| NCT05951595 | Phase 3 | Jan 1, 2024 | Mahidol University, University of Oxford |
| NCT05946642 | Phase 3 | Jul 15, 2023 | Malaria Consortium |
| NCT06076213 | Phase 4 | May 1, 2023 | Centers for Disease Control and Prevention (CDC), Global Health Innovative Technology Fund, Government of the Democratic Republic of the Congo |
| NCT05764746 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2023 | Muhimbili University, The Swedish Research Council, Uppsala University |
| NCT05550909 | Phase 2 | Oct 17, 2022 | Malaria Research and Training Center, Bamako, Mali, University of London |
| NCT06300970 | Phase 4 | Aug 9, 2022 | Centers for Disease Control and Prevention (CDC), Government of Liberia |
| NCT05471544 | Phase 3 | Jul 18, 2022 | Malaria Consortium |
| NCT05478954 | Phase 4 | Jul 15, 2022 | Malaria Consortium |
| NCT05354258 | N/A | Jun 16, 2022 | University of London |
| NCT05323721 | Phase 4 | Jun 1, 2022 | Government of Uganda, Malaria Consortium |
| NCT05343312 | Phase 4 | Mar 16, 2022 | United States Agency for International Development |
| NCT05081089 | Phase 2 | Oct 12, 2021 | Malaria Research and Training Center, Bamako, Mali, University of London |
| NCT04816461 | Phase 4 | Jul 31, 2021 | Institut et Haute école de la Santé, La Source |
| NCT04829695 | Phase 4 | Apr 5, 2021 | Association Camerounaise pour le Marketing Social (ACMS), Cameroon, Government of Cameroon, Impact Malaria, Cameroon, University of Yaounde |
| NCT04618523 | Phase 4 | Oct 26, 2020 | Government of Congo, Government of the Democratic Republic of the Congo, University of Kinshasa, World Health Organization |
| NCT04532931 | Phase 2 | Sep 3, 2020 | Medicines for Malaria Venture, Shin Poong Pharmaceuticals |
Organizations
Research & Development (144)
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Parke-Davis | For profit | NDA | Jun 1, 1950 |